BACKGROUND AND OBJECTIVES: The discovery of fibroblast growth factor-23 (FGF-23) and the elucidation of its function as a phosphaturic and 1,25(OH)2VitD counter-regulatory hormone provides a new conceptual framework for the understanding of the pathogenesis of secondary hyperparathyroidism. This study aims to elucidate the complex associations between FGF-23, parathyroid hormone (PTH), 1,25(OH)2D, and phosphate in patients with early-stage chronic kidney disease (CKD) and to provide clinical evidence in favor of the new phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum biointact PTH and FGF-23, 25(OH)D, 1,25(OH)2D, calcium, phosphate, 24-hour urine excretion of phosphate and calcium, and urinary fractional excretion of phosphate were determined in a cross-sectional study including 125 patients with CKD stages 1 to 3. RESULTS: Serum phosphate levels showed an inverse association with estimated GFR (eGFR), but were within the normal range in all but one patient. FGF-23 and PTH were inversely associated with eGFR, even in the subgroup of patients with CKD stages 1 and 2. High FGF-23 levels were significantly more prevalent than high PTH levels. The urinary fractional excretion of phosphate was highest in patients with both a high serum FGF-23 and PTH level. Increased FGF-23 and phosphate and decreased 25(OH)D were independently associated with decreased 1,25(OH)2D. CONCLUSIONS: Our data are in favor of the new paradigm for the pathogenesis of secondary hyperparathyroidism according to which a reduced phosphate excretion capacity is the principal abnormality that initiates secondary hyperparathyroidism.
BACKGROUND AND OBJECTIVES: The discovery of fibroblast growth factor-23 (FGF-23) and the elucidation of its function as a phosphaturic and 1,25(OH)2VitD counter-regulatory hormone provides a new conceptual framework for the understanding of the pathogenesis of secondary hyperparathyroidism. This study aims to elucidate the complex associations between FGF-23, parathyroid hormone (PTH), 1,25(OH)2D, and phosphate in patients with early-stage chronic kidney disease (CKD) and to provide clinical evidence in favor of the new phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum biointact PTH and FGF-23, 25(OH)D, 1,25(OH)2D, calcium, phosphate, 24-hour urine excretion of phosphate and calcium, and urinary fractional excretion of phosphate were determined in a cross-sectional study including 125 patients with CKD stages 1 to 3. RESULTS: Serum phosphate levels showed an inverse association with estimated GFR (eGFR), but were within the normal range in all but one patient. FGF-23 and PTH were inversely associated with eGFR, even in the subgroup of patients with CKD stages 1 and 2. High FGF-23 levels were significantly more prevalent than high PTH levels. The urinary fractional excretion of phosphate was highest in patients with both a high serum FGF-23 and PTH level. Increased FGF-23 and phosphate and decreased 25(OH)D were independently associated with decreased 1,25(OH)2D. CONCLUSIONS: Our data are in favor of the new paradigm for the pathogenesis of secondary hyperparathyroidism according to which a reduced phosphate excretion capacity is the principal abnormality that initiates secondary hyperparathyroidism.
Authors: Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray Journal: J Am Soc Nephrol Date: 2008-11-12 Impact factor: 10.121
Authors: Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow Journal: J Am Soc Nephrol Date: 2004-08 Impact factor: 10.121
Authors: Emilio González-Parra; Álvaro Aceña; Óscar Lorenzo; Nieves Tarín; María Luisa González-Casaus; Carmen Cristóbal; Ana Huelmos; Ignacio Mahíllo-Fernández; Ana María Pello; Rocío Carda; Ignacio Hernández-González; Joaquín Alonso; Fernando Rodríguez-Artalejo; Lorenzo López-Bescós; Alberto Ortiz; Jesús Egido; José Tuñón Journal: J Bone Miner Metab Date: 2015-08-23 Impact factor: 2.626
Authors: Sophie de Seigneux; Marie Courbebaisse; Joseph M Rutkowski; Alexandra Wilhelm-Bals; Marie Metzger; Stellor Nlandu Khodo; Udo Hasler; Hassib Chehade; Eva Dizin; Arezoo Daryadel; Bénedicte Stengel; E Girardin; Dominique Prié; Carsten A Wagner; Philipp E Scherer; Pierre-Yves Martin; Pascal Houillier; Eric Feraille Journal: J Am Soc Nephrol Date: 2014-10-27 Impact factor: 10.121
Authors: Marcella D Walker; Thomas Nickolas; Anna Kepley; James A Lee; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg Journal: J Clin Endocrinol Metab Date: 2014-02-14 Impact factor: 5.958
Authors: Jin Xia; Wanzhu Tu; JoAnn E Manson; Hongmei Nan; Aladdin H Shadyab; Jennifer W Bea; Ting-Yuan D Cheng; Lifang Hou; Yiqing Song Journal: Am J Clin Nutr Date: 2020-08-01 Impact factor: 7.045